Literature DB >> 21677312

Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.

Mary Eapen1, Jennifer Le Rademacher, Joseph H Antin, Richard E Champlin, Jeanette Carreras, Joseph Fay, Jakob R Passweg, Jakub Tolar, Mary M Horowitz, Judith C W Marsh, H Joachim Deeg.   

Abstract

Outcome after unrelated donor bone marrow (BM) transplantation for severe aplastic anemia (SAA) has improved, with survival rates now approximately 75%. Increasing use of peripheral blood stem and progenitor cells (PBPCs) instead of BM as a graft source prompted us to compare outcomes of PBPC and BM transplantation for SAA. We studied 296 patients receiving either BM (n = 225) or PBPC (n = 71) from unrelated donors matched at human leukocyte antigen-A, -B, -C, -DRB1. Hematopoietic recovery was similar after PBPC and BM transplantation. Grade 2 to 4 acute graft-versus-host disease risks were higher after transplantation of PBPC compared with BM (hazard ratio = 1.68, P = .02; 48% vs 31%). Chronic graft-versus-host disease risks were not significantly different after adjusting for age at transplantation (hazard ratio = 1.39, P = .14). Mortality risks, independent of age, were higher after PBPC compared with BM transplantation (hazard ratio = 1.62, P = .04; 76% vs 61%). These data indicate that BM is the preferred graft source for unrelated donor transplantation in SAA.

Entities:  

Mesh：

Year:  2011        PMID： 21677312      PMCID： PMC3167362          DOI： 10.1182/blood-2011-05-354001

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Pathophysiology and treatment of graft-versus-host disease.

Authors:  M E Flowers; E Kansu; K M Sullivan
Journal:  Hematol Oncol Clin North Am       Date:  1999-10       Impact factor: 3.722

Review 2.  Guidelines for the diagnosis and management of aplastic anaemia.

Authors:  Judith C W Marsh; Sarah E Ball; Jamie Cavenagh; Phil Darbyshire; Inderjeet Dokal; Edward C Gordon-Smith; Jane Keidan; Andrew Laurie; Anna Martin; Jane Mercieca; Sally B Killick; Rhona Stewart; John A L Yin
Journal:  Br J Haematol       Date:  2009-08-10       Impact factor: 6.998

3.  Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy.

Authors:  H Joachim Deeg; Margaret O'Donnell; Jakub Tolar; Rajni Agarwal; Richard E Harris; Stephen A Feig; Mary C Territo; Robert H Collins; Peter A McSweeney; Edward A Copelan; Shakila P Khan; Ann Woolfrey; Barry Storer
Journal:  Blood       Date:  2006-05-09       Impact factor: 22.113

4.  Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome.

Authors:  Stephen Rosenfeld; Dean Follmann; Olga Nunez; Neal S Young
Journal:  JAMA       Date:  2003-03-05       Impact factor: 56.272

Review 5.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young; Rodrigo T Calado; Phillip Scheinberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

Review 6.  Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia.

Authors:  D A Margolis; J T Casper
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

7.  Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.

Authors:  Hubert Schrezenmeier; Jakob R Passweg; Judith C W Marsh; Andrea Bacigalupo; Christopher N Bredeson; Eduardo Bullorsky; Bruce M Camitta; Richard E Champlin; Robert Peter Gale; Monika Fuhrer; John P Klein; Anna Locasciulli; Rosi Oneto; Antonius V M B Schattenberg; Gerard Socie; Mary Eapen
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

8.  Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients.

Authors:  H J Deeg; G Socié; G Schoch; M Henry-Amar; R P Witherspoon; A Devergie; K M Sullivan; E Gluckman; R Storb
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.

Authors:  G Socié; M Henry-Amar; A Bacigalupo; J Hows; A Tichelli; P Ljungman; S R McCann; N Frickhofen; E Van't Veer-Korthof; E Gluckman
Journal:  N Engl J Med       Date:  1993-10-14       Impact factor: 91.245
  10 in total
  44 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

2.  Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants.

Authors:  S Masouridi-Levrat; F Simonetta; Y Beauverd; O Tsopra; Y Tirefort; C Stephan; E Levrat; M Ansari; F Verholen; E Roosnek; J R Passweg; Y Chalandon
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

Review 3.  Alternative donor transplants for severe aplastic anemia.

Authors:  Andrea Bacigalupo
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 4.  The diagnosis and treatment of aplastic anemia: a review.

Authors:  Maurizio Miano; Carlo Dufour
Journal:  Int J Hematol       Date:  2015-04-03       Impact factor: 2.490

Review 5.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

6.  Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups.

Authors:  Andrea Bacigalupo; Gérard Socié; Hubert Schrezenmeier; Andre Tichelli; Anna Locasciulli; Monika Fuehrer; Antonio M Risitano; Carlo Dufour; Jakob R Passweg; Rosi Oneto; Mahmoud Aljurf; Catherine Flynn; Valerie Mialou; Rose Marie Hamladji; Judith C W Marsh
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

7.  Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years.

Authors:  Xia Qin; Yi-Ping Zhu; Cheng-Juan Luo; Ming Zhou; Ke Huang; Chun Chen; Wei-Ping Zhang; Yuan Sun; Rong-Mu Luo; Xiang-Feng Tang; Ting Yang; Xian-Min Song; Shao-Yan Hu; Zi-Min Sun; Jiong Hu; Shun-Qing Wang; Jing Chen
Journal:  Ann Hematol       Date:  2021-05-14       Impact factor: 3.673

Review 8.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

9.  Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia.

Authors:  Daniel A Keesler; Andrew St Martin; Carmem Bonfim; Adriana Seber; Mei-Jie Zhang; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-22       Impact factor: 5.742

10.  Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy.

Authors:  L Gao; Y Li; Y Zhang; X Chen; L Gao; C Zhang; Y Liu; P Kong; Q Wang; Y Su; C Wang; S Wang; B Li; A Sun; X Du; D Zeng; J Li; H Liu; X Zhang
Journal:  Bone Marrow Transplant       Date:  2014-01-27       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.